Paper
0
Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
Authors
Joshua Zeidner,Junichiro Yuda
Justin Watts,Mark Levis,Harry Erba,Kentaro Fukushima,Takahiro Shima,Neil Palmisiano,Eunice Wang,Uma Borate,Joseph Brandwein,Cristina Papayannidis,Pau Montesinos,Gina Keiffer,Yasushi Miyazaki,Naoko Hosono,Takayuki Ikezoe,Yoshiaki Ogawa,Timothy Pardee,Stephen Strickland,Koichi Onodera,Shang-Ju Wu,Melissa Ooi,Emmanuel Raffoux,Susana Vives,Alireza Eghtedar,Hongliang Cai,Curtis Allred,Bo Xu,Paul Robson,Akinobu Watanabe,Matthew Hitron,Jatin Shah,Hagop Kantarjian
+32 authors
,Naval DaverJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave